Exploring Privileged Heterocyclic Scaffolds: | Their Scope as Novel Anti-Inflammatory Drug Candidates

Rajeev Kharb

ISBN 10: 6139900891 / ISBN 13: 9786139900893

Published by LAP LAMBERT Academic Publishing, 2018

About this Item

Exploring Privileged Heterocyclic Scaffolds: | Their Scope as Novel Anti-Inflammatory Drug Candidates | Rajeev Kharb | Taschenbuch | 88 S. | Englisch | 2018 | LAP LAMBERT Academic Publishing | EAN 9786139900893 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Seller Inventory # 114472757

Bibliographic Details

• Title: Exploring Privileged Heterocyclic Scaffolds: | Their Scope as Novel Anti-Inflammatory Drug Candidates
• Publisher: LAP LAMBERT Academic Publishing
• Publication Date: 2018
• Language: English
• ISBN 10: 6139900891
• ISBN 13: 9786139900893
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 6D millimeters 220 millimeters width by 150 millimeters height by 6 millimeters depth
• Weight: 149 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

Inflammation is characterized by redness, heat, swelling, pain and sometimes loss of function of tissues. Cyclooxygenases (COXs) are mainly responsible for inflammation. Constitutive COX-1 is responsible for providing cytoprotection in gastrointestinal (GI) tract whereas inducible COX-2 facilitates inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat the signs and symptoms of inflammation. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, Diclofenac, Flurbiprofen and Ibuprofen act via the inhibition of the COX-1 isoenzyme or the combined inhibition of COX-1 and COX-2 isoenzymes. However they show greater selectivity for COX-1 than COX-2 as well as produce serious side effect like hepatic toxicity. Therefore, it is urgently required to identify new targets that are essential for the design and development of novel anti-inflammatory agents as an alternative to NSAIDs. The relevant information provided in this manuscript can be found useful for drug design of novel anti-inflammatory agents having greater safety, selectivity and potency as well as lesser side effects.